January 19, 2023

Inequities in cancer treatments after COVID-19 infection

By: Judy Mathias

Editor's Note

This study led by researchers at Columbia University Irving Medical Center, New York City, finds that race, ethnicity, and area-level social determinants of health (SDOH) were associated with delayed or discontinued cancer treatments and longer delays to restart drug-based therapies after COVID-19 infections.

The analysis included data on 4,768 patients enrolled in the American Society for Clinical Oncology COVID-19 Registry collected from April 1, 2020, to September 26, 2022.

Among the findings:

  • Compared with non-Hispanic White patients, Hispanic and non-Hispanic Black patients were more likely to experience a delay of at least 14 days or discontinuation of any treatment and drug-based treatment.
  • Area-level SDOH (eg, geography, proportion of residents without health insurance or with only a high school education, and lower median household income) were associated with delayed or discontinued treatment.
  • In multivariate analysis, Hispanic, non-Hispanic, Asian American or Pacific Islander, and non-Hispanic Black patients experienced longer delays to restarting pharmacotherapy compared with non-Hispanic White patients.

The researchers concluded that such treatment delays could exacerbate cancer survival inequities in the US for years to come.

JAMA (healthcare publication) Network logo



Get OR Manager Updates

Sign Up Now
Latest Issue of OR Manager
September 2023
Video Spotlight
Live chat by BoldChat